

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

021825Orig1s000

CROSS DISCIPLINE TEAM LEADER REVIEW

Cross-Discipline Team Leader Review

Date	September 28, 2011
From	Kathy M. Robie Suh, M.D., Ph.D.
Subject	Cross-Discipline Team Leader Review
NDA/BLA #	21-825
Supplement#	
Applicant	ApoPharma Inc.
Date of Submission	April 13, 2011
PDUFA Goal Date	October 14, 2011
Proprietary Name / Established (USAN) names	Ferriprox (deferiprone)
Dosage forms / Strength	500 mg film-coated tablets
Proposed Indication(s)	for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate
Recommended:	Approval for revised indication: “for the treatment of patients with transfusional iron overload in patients with thalassemia syndromes when current chelation therapy is inadequate”

Cross Discipline Team Leader Review Template

1. Introduction

Ferriprox (deferiprone) is an orally active iron chelator developed for use in treating iron overload. This is the second review cycle for this product. The NDA was initially submitted 1/29/2009 for the indication, “treatment of iron overload in patients with transfusion-dependent thalassemia and for treatment in patients with other transfusion-dependent anemias for whom the use of other iron chelators has been considered inappropriate”. A complete response (CR) letter was issued on 11/30/2009. The current resubmission (received 4/14/2011) seeks approval of deferiprone for the indication: “for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.” The proposed dose is deferiprone 25 to 33 mg/kg body weight, orally, three times a day for a total daily dose of 75 to (b)(4) mg/kg body weight.

2. Background

Patients with certain inherited anemias (importantly β -thalassemia and increasingly sickle cell disease in the U.S.) require frequent transfusion of red blood cells beginning at a young age to offset anemia that occurs because of inability to manufacture normal hemoglobin. Normal dietary absorption is about 1 mg daily which maintains a total body iron of approximately 3 to 5 grams in adults. One unit of packed red blood cells contains about 200 mg of iron. Because the body has no physiologic mechanism to excrete excess iron, repeated red blood cell

transfusions over time result in massive iron overload. The excess iron becomes deposited in tissues and causes tissue damage due to iron-catalyzed peroxidation of membrane lipids and leads to morbidity and often eventually mortality, mainly due to cardiac damage. The liver and endocrine organs also are notably affected. Assessment of liver iron content (LIC) has been the generally accepted standard for assessment of body iron burden; however, serum ferritin, a nonspecific parameter, is commonly followed clinically.

Currently available treatment options for management of iron overload due to transfusions include Desferal (deferoxamine mesylate), an injectable iron chelator approved in 1968 and Exjade (deferasirox), an orally active iron chelator approved in 2005.

Deferiprone binds iron in a 3:1 complex which is then excreted in the urine. The drug was first administered to humans in 1987, was approved in the European Union in 1999 and currently is approved in 61 countries, mostly for the indication of the treatment of iron overload in patients with thalassemia major when deferoxamine therapy is contraindicated or inadequate.

The initial NDA submission provided a single randomized controlled trial (Study LA16-0102) comparing the use of deferiprone versus the use of deferoxamine in removing excess cardiac iron in subjects with thalassemia major. The study used a primary efficacy endpoint that employed magnetic resonance imaging of the heart (cardiac MRI) with measurement of a parameter termed T2* (T2 star) to evaluate extent of iron overload and effectiveness of chelation therapy. The primary efficacy analysis showed a 3.9 msec increase in cardiac MRI T2* from baseline to 12 months in the deferiprone treatment group and 2.3 msec increase in the deferoxamine treatment group but no significant correlation between change in cardiac MRI T2* and measures of cardiac function and there were no differences between treatments in change in liver iron concentration (LIC). A complete response (CR) letter was issued on 11/30/2009 citing a number of clinical deficiencies and well as deficiencies for Clinical Pharmacology, product quality, and facility inspections. See Dr. George Shashaty's Clinical Review (10/19/2009) for details of the first cycle clinical review. See my Cross-Disciplinary Team Leader (CDTL) review (11/25/2009; addendum 12/31/2009) and Dr. Dwaine Rieves' Division Director Summary Review (11/20/2009) for a summary of issues from the first cycle review.

The current resubmission narrows the indication from the initially proposed "treatment of iron overload in patients with transfusion-dependent thalassemia and treatment of iron overload in patients with other transfusion-dependent anemias for whom the use of other iron chelators has been considered inappropriate" to the currently proposed "treatment of patients with transfusional iron overload when current chelation therapy is inadequate." A single retrospective, single-arm study (LA36-0310) is submitted for the indication. Results of the study are discussed under section "7. Clinical/Statistical –Efficacy" below.

3. CMC

The Chemistry, Manufacturing and Controls (CMC) Review (W.M. Adams, Ph.D., final signature 9/27/2009) states, "From a CMC standpoint, this application is recommended for

approval pending the receipt of an overall acceptable recommendation from the Office of Compliance. The submission is complete and all other CMC review issues have been resolved. Insert the following language into the action letter: Based on the stability data provided in your application, the drug product is granted a 24-month expiry when stored at USP controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).” There are no CMC recommendations for post-marketing commitments.

4. Nonclinical Pharmacology/Toxicology

Pharmacology/Toxicology Review during the first cycle noted that lifetime carcinogenicity studies had not been conducted but the sponsor’s proposal to conduct a 2-year carcinogenicity study in rats and a 6-month study in p53 knockout mice during Phase 4 is adequate. Pharmacology found the application acceptable for approval with appropriate warnings in the product labeling regarding the genotoxicity and carcinogenic risk and fetal and developmental toxicity (Pregnancy Category C) (D. E. Bailey, Ph.D. (reviews signed 6/27/07, 8/4/08 and 9/22/09). At the time of this CDTL review Pharmacology/Toxicology review for the current review cycle has not been finalized.

5. Clinical Pharmacology/Biopharmaceutics

Clinical Pharmacology review was completed by Joseph Grillo, Pharm.D. (final signature, 9/21/2011). The review stated that, “From a clinical pharmacology perspective, this resubmission of the original application is ACCEPTABLE provided that the applicant and the Agency come to a mutually satisfactory agreement regarding the language in the package insert and the applicant commits to the following post marketing commitments addressing clinical pharmacology related safety concerns with deferiprone treatment.” Recommended postmarketing requirements included that the sponsor: Conduct a pharmacokinetic trial of both deferiprone and its primary 3-O-glucuronide metabolite in subjects with hepatic impairment; conduct a pharmacokinetic trial of both deferiprone and its primary 3-O-glucuronide metabolite in subjects with renal impairment and; conduct a TQT assessment for deferiprone. In addition, the review recommended that the sponsor conduct *in vitro* studies to determine the affect of moderate to strong UDP glucuronosyltransferase (UGT) inhibition and moderate to strong UGT induction on the metabolism of deferiprone to determine the need for additional *in vivo* drug interaction trials. Additional comments for the sponsor were included in the review.

In an additional consultation review at the request of the Division of Hematology Products, Clinical Pharmacology reviewed the bioavailability of the deferiprone solution formulation used in ApoPharma's pediatric study LA30-0307 compared to the bioavailability of the to-be-marketed tablets (Joseph Grillo, Pharm.D., final signature 9/21/2011). The review found that the deferiprone solution formulation used in the submitted bioequivalence study (LA21-BE) is bioequivalent to the Ferriprox tablet formulation. The same deferiprone solution formulation was used in trial LA30-0307. Clinical Pharmacology deferred to CMC regarding the integrity of the deferiprone solution batches used in these studies.

The Office of New Drugs Quality Assessment (ONDQA) review conducted by Tien-Mien Chen, Ph.D. (9/16/2011) identified a need for the sponsor to revise the dissolution acceptance criterion to change from “Q = (b) (4)” and indicated that the sponsor needed to provide an updated specification sheet for the product including the revised criterion for the dissolution test. The deficiency was communicated to the sponsor and the sponsor replied. Review of the sponsor’s reply (9/25/2011 review, signed by Angelica Dorantes, Ph.D.) found the sponsor’s response acceptable agreeing with the sponsor that the provided dissolution data support an acceptance criterion of Q= (b) (4) in 45 minutes and concluded that, “From the Biopharmaceutics perspective, NDA 21-825 is recommended for approval.”

6. Clinical Microbiology

N/A

7. Clinical/Statistical- Efficacy

In this resubmission a single study (LA36-0310) in which data from patients in the completed studies identified as being inadequately treated with other iron chelators were analyzed examining change in serum ferritin levels from baseline up to one year after starting deferiprone was submitted. The sponsor’s primary efficacy analysis showed 136 of 264 patients (52%) had a 20% or greater decrease in serum ferritin from baseline to end of study. See the Clinical Review (Dr. George Shashaty, 9/16/2011), the Statistical Review (Qing Xu, Ph.D., 9/16/2011) and my Medical Team Leader review (signed 9/27/2011) for detailed presentation and discussion of Study LA36-0310. The Clinical and Statistical reviews identified a number of deficiencies of the study design (including that it was retrospective, single arm, pooled patients from heterogeneous studies and had limited information on prior treatment) that limit interpretation of the study results.

The Clinical Review (Dr. George Shashaty, 9/16/2011) recommended that, “if the sponsor agrees to change the indication to “the treatment of patients with thalassemia with transfusional iron overload when previous chelation therapy with other approved iron chelators has been unsuccessful”, deferiprone should receive Accelerated Approval under the requirements of 21CFR314.500-314.560 (Subpart H- Accelerated Approval of New Drugs for Serious of Life-Threatening Illnesses). The Secondary Medical Team Review concurs with the recommendation of Accelerated Approval for the indication revised as per Dr. Shashaty (Kathy Robie Suh, M.D., Ph.D., signed 9/27/2011)

8. Safety

Updated safety information was reviewed by Dr. George Shashaty in his Clinical Review (9/16/2011). The safety profile of deferiprone for the resubmission is not changed from the profile described during the first cycle review. The major safety consideration is agranulocytosis which occurred in 1.7% of patients in the clinical studies. In the post-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.